Proposed internal deadlines—not regulatory deadlines.
| Owner | Deliverable | Evidence of completion |
|---|---|---|
| Medical director | Review the FDA safety communication | Approved patient-message and escalation changes |
| COO | Classify recent interrupted-access cases | Separate operational, affordability and clinical categories |
| Compliance lead | Correct the DSCSA register where applicable | Documented entity-level exemption assessment |
| CFO | Audit promotional-price assumptions | Introductory and continuing costs shown separately |
| Procurement | Challenge the largest partner’s fallback plan | Named alternative, acceptance criteria and escalation contact |
Take to the next procurement meeting: one anonymised failed order, one current patient-price example and one supplier compliance assertion that still lacks evidence.
This briefing supports procurement decisions; it does not authorise a supply route or recommend treatment changes.
Explore the table row by row
A working view of the research
Medical director
- Deliverable
- Review the FDA safety communication
- Evidence of completion
- Approved patient-message and escalation changes
Sources cited on this page
See the section’s source register for the research context.
Section sources →